OpenURL Connection Search

Select item for more details and to access through your institution.

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Published in:
Cancer Immunology, Immunotherapy, 2019, v. 68, n. 5, p. 787, doi. 10.1007/s00262-019-02313-z
By:
- Werter, Inge M.;
- Huijts, Charlotte M.;
- Lougheed, Sinéad. M.;
- Hamberg, Paul;
- Polee, Marco B.;
- Tascilar, Metin;
- Los, Maartje;
- Haanen, John B. A. G.;
- Helgason, Helgi H.;
- Verheul, Henk M.;
- de Gruijl, Tanja D.;
- van der Vliet, Hans J.
Publication type:
Article
Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.
Published in:
2019
By:
- Kwakman, Johannes J M;
- van Werkhoven, Erik;
- Simkens, Lieke H J;
- van Rooijen, Johan M;
- van de Wouw, Yes A J;
- Tije, Albert J Ten;
- Creemers, Geert-Jan M;
- Hendriks, Mathijs P;
- Los, Maartje;
- van Alphen, Robbert J;
- Polée, Marco B;
- Muller, Erik W;
- van der Velden, Ankie M T;
- van Voorthuizen, Theo;
- Koopman, Miriam;
- Mol, Linda;
- Punt, Cornelis J A
Publication type:
clinical trial
Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
Published in:
Journal of Surgical Oncology, 2021, v. 124, n. 4, p. 589, doi. 10.1002/jso.26567
By:
- Brada, Lilly J. H.;
- Walma, Marieke S.;
- Daamen, Lois A.;
- van Roessel, Stijn;
- van Dam, Ronald M.;
- de Hingh, Ignace H.;
- Liem, Mike L. S.;
- de Meijer, Vincent E.;
- Patijn, Gijs A.;
- Festen, Sebastiaan;
- Stommel, Martijn W. J.;
- Bosscha, Koop;
- Polée, Marco B.;
- Yung Nio, C.;
- Wessels, Frank J.;
- de Vries, Jan J. J.;
- van Lienden, Krijn P.;
- Bruijnen, Rutger C.;
- Los, Maartje;
- Mohammad, Nadia Haj
Publication type:
Article
Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
Published in:
2021
By:
- Wensink, G. Emerens;
- Elferink, Marloes A. G.;
- May, Anne M.;
- Mol, Linda;
- Hamers, Patricia A. H.;
- Bakker, Sandra D.;
- Creemers, Geert-Jan;
- de Groot, Jan Willem B.;
- de Klerk, Gerty J.;
- Haberkorn, Brigitte C. M.;
- Haringhuizen, Annebeth W.;
- Hoekstra, Ronald;
- Hunting, J. Cornelis B.;
- Kerver, Emile D.;
- Mathijssen-van Stein, Danielle;
- Polée, Marco B.;
- Pruijt, Johannes F. M.;
- Quarles van Ufford-Mannesse, Patricia;
- Radema, Sandra;
- Rietbroek, Ronald C.
Publication type:
journal article
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Published in:
2016
By:
- Meulendijks, Didier;
- de Groot, Jan Willem B.;
- Los, Maartje;
- Boers, James E.;
- Beerepoot, Laurens V.;
- Polee, Marco B.;
- Beeker, Aart;
- Portielje, Johanna E.A.;
- Goey, Swan H.;
- de Jong, Robert S.;
- Vanhoutvin, Steven A.L.W.;
- Kuiper, Maria;
- Sikorska, Karolina;
- Pluim, Dick;
- Beijnen, Jos H.;
- Schellens, Jan H.M.;
- Grootscholten, Cecile;
- Tesselaar, Margot E.T.;
- Cats, Annemieke
Publication type:
journal article

Found: 5

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.

Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.